BioSpace News Archive

Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced that Jake Bauer joined the company’s Board of Directors as an independent director.

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, announced it will release its second quarter 2021 financial results on Tuesday, August 10, 2021 before the open of the U.S. financial markets.

HUTCHMED Limited, the innovative, commercial-stage biopharmaceutical company, reports its unaudited financial results for the six months ended June 30, 2021 and provides updates on key clinical and commercial developments since the start of the year.

Karyopharm Therapeutics Inc. announced dosing of the first patients in two new company-sponsored Phase 2 and 1/2 clinical studies evaluating XPOVIO®, the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export compound in combination with approved therapies in patients with advanced melanoma and in patients with treatment naïve myelofibrosis.

PYC Therapeutics, a biotechnology company combining two complementary platform technologies to develop a new generation of RNA therapeutics to change the lives of patients with inherited diseases, announced a second quarter update highlighting the progress of its development pipeline, growth of its U.S. operations and upcoming milestones.

Paragon Genomics, Inc. reported publication of three scientific studies confirming that its CleanPlex® SARS-CoV-2 Research and Surveillance Panel for viral detection, mutation analysis, variant tracking and epidemiological research accurately identifies important COVID-19 variants, such as the B.1.1.7 Alpha variant and the B.1.617.2 Delta variant, major variants of concern that have been implicated in surges of COVID-19 infections worldwide.

Orthofix Medical Inc., a global medical device company with a spine and orthopedics focus, announced the launch and first patient implants with the fiberFUSE™ Strip, an advanced demineralized fiber bone-graft solution containing cancellous bone.

Castle Biosciences, Inc., a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, Aug. 11, 2021, at 3:30 p.m. Eastern time.

Synchron, a venture-backed brain data transfer company, announced that the U.S. Food and Drug Administration has approved its Investigational Device Exemption application for its flagship product, the StentrodeTM motor neuroprosthesis.

Lantheus Holdings, Inc., an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, reported financial results for its second quarter ended June 30, 2021.